Menarini Asia-Pacific Partners with Pharmacosmos to Distribute Cosela in Asia-Pacific
Menarini Asia-Pacific has partnered exclusively with Pharmacosmos to register, commercialise, and distribute Cosela (trilaciclib) across Asia-Pacific markets, including Australia, Singapore, and South Korea. Cosela is an FDA-approved, first-in-class therapy designed to protect bone marrow from chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer. This collaboration aims to improve oncology supportive care by expanding patient access to this innovative treatment across multiple countries in the region.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 35/100.
Outlets measured: thetribune, thehindu. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (62–70/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thehindu broke this story on 21 Jul, 03:08 am. Other outlets followed.